The senescence journey in cancer immunoediting

被引:19
|
作者
Zingoni, Alessandra [1 ]
Antonangeli, Fabrizio [2 ]
Sozzani, Silvano [1 ]
Santoni, Angela [1 ,3 ]
Cippitelli, Marco [1 ]
Soriani, Alessandra [1 ]
机构
[1] Sapienza Univ Rome, Fdn Cenci Bolognetti, Ist Pasteur Italia, Dept Mol Med, I-00161 Rome, Italy
[2] Natl Res Council CNR, Inst Mol Biol & Pathol, I-00185 Rome, Italy
[3] IRCCS Neuromed, I-86077 Pozzilli, Italy
关键词
Cancer; Senescence; SASP; Immunoediting; Immunosurveillance; Dormancy; Senotherapy; MESENCHYMAL STROMAL CELLS; NF-KAPPA-B; CELLULAR SENESCENCE; T-CELLS; DNA-DAMAGE; SECRETORY PHENOTYPE; TUMOR DORMANCY; PROMOTES SENESCENCE; ADAPTIVE IMMUNITY; NKG2D LIGANDS;
D O I
10.1186/s12943-024-01973-5
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cancer progression is continuously controlled by the immune system which can identify and destroy nascent tumor cells or inhibit metastatic spreading. However, the immune system and its deregulated activity in the tumor microenvironment can also promote tumor progression favoring the outgrowth of cancers capable of escaping immune control, in a process termed cancer immunoediting. This process, which has been classified into three phases, i.e. "elimination", "equilibrium" and "escape", is influenced by several cancer- and microenvironment-dependent factors. Senescence is a cellular program primed by cells in response to different pathophysiological stimuli, which is based on long-lasting cell cycle arrest and the secretion of numerous bioactive and inflammatory molecules. Because of this, cellular senescence is a potent immunomodulatory factor promptly recruiting immune cells and actively promoting tissue remodeling. In the context of cancer, these functions can lead to both cancer immunosurveillance and immunosuppression. In this review, the authors will discuss the role of senescence in cancer immunoediting, highlighting its context- and timing-dependent effects on the different three phases, describing how senescent cells promote immune cell recruitment for cancer cell elimination or sustain tumor microenvironment inflammation for immune escape. A potential contribution of senescent cells in cancer dormancy, as a mechanism of therapy resistance and cancer relapse, will be discussed with the final objective to unravel the immunotherapeutic implications of senescence modulation in cancer.
引用
收藏
页数:21
相关论文
共 50 条
  • [31] Cancer Immunoediting by Innate Lymphoid Cells
    Wagner, Marek
    Koyasu, Shigeo
    TRENDS IN IMMUNOLOGY, 2019, 40 (05) : 415 - 430
  • [32] Cancer Immunoediting in Malignant Glioma COMMENTS
    Lampson, Lois A.
    Jackson, Christopher
    NEUROSURGERY, 2012, 71 (02) : 222 - 223
  • [33] Type I interferon and cancer immunoediting
    Smyth, MJ
    NATURE IMMUNOLOGY, 2005, 6 (07) : 646 - 648
  • [34] Therapeutic applications of the cancer immunoediting hypothesis
    Desai, Rupen
    Coxon, Andrew T.
    Dunn, Gavin P.
    SEMINARS IN CANCER BIOLOGY, 2022, 78 : 63 - 77
  • [35] Type I interferon and cancer immunoediting
    Mark J Smyth
    Nature Immunology, 2005, 6 : 646 - 648
  • [36] Revisiting cancer immunoediting by understanding cancer immune complexity
    Manjili, Masoud H.
    JOURNAL OF PATHOLOGY, 2011, 224 (01): : 5 - 9
  • [37] Cancer immunoediting and immune dysregulation in multiple myeloma
    Nakamura, Kyohei
    Smyth, Mark J.
    Martinet, Ludovic
    BLOOD, 2020, 136 (24) : 2731 - 2740
  • [38] Cancer Immunoediting in the Era of Immuno-oncology
    Gubin, Matthew M.
    Vesely, Matthew D.
    CLINICAL CANCER RESEARCH, 2022, 28 (18) : 3917 - 3928
  • [39] Lessons from Cancer Immunoediting in Cutaneous Melanoma
    Aris, Mariana
    Barrio, Maria Marcela
    Mordoh, Jose
    CLINICAL & DEVELOPMENTAL IMMUNOLOGY, 2012,
  • [40] Cancer immunoediting is associated with checkpoint inhibitor response
    Ring, S. S.
    Pop, O. T.
    Pozniak, J.
    Berner, F.
    Ali, Hasan O.
    Abdou, M. -T.
    Diem, S.
    Bomze, D.
    Niederer, R.
    Faesler, M.
    Landeloos, E.
    Rambow, F.
    Bervoets, G.
    Freiberger, S. N.
    Mayr, T.
    Muders, M.
    van den Broek, M.
    Bald, T.
    Landsberg, J.
    Dietrich, D.
    Mangana, J.
    Cozzio, A.
    Garbe, C.
    Dummer, R.
    Jochum, W.
    Levesque, M. P.
    Ludewig, B.
    Bechter, O.
    Marine, J. -C.
    Tuting, T.
    Holzel, M.
    Flatz, L.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 14 - 14